Triggering receptor expressed on myeloid cells 2
Triggering receptor expressed on myeloid cells 2 (TREM2) is a myeloid-cell surface receptor encoded by the TREM2 gene.
Triggering receptor expressed on myeloid cells 2 (TREM2) is a myeloid-cell surface receptor encoded by the TREM2 gene. It is expressed prominently in cells of the innate immune system, including microglia and macrophage populations, where it participates in sensing tissue damage, regulating inflammatory responses, and supporting cell survival and differentiation. In biomedical research, TREM2 is widely studied as a disease-associated immune regulator rather than as a classical enzyme or structural protein target.
TREM2 has attracted substantial attention in neurodegeneration, especially Alzheimer’s disease, where genetic variants are associated with increased risk and altered microglial function. It is also increasingly implicated in metabolic and fibrotic disease states, including Metabolic dysfunction associated steatohepatitis and liver fibrosis, where TREM2-expressing macrophage subsets appear to contribute to disease-associated immune remodeling. Because of these roles, TREM2 is being explored both as a mechanistic biomarker and as a therapeutic target.
Where the papers sit
9 papers from the last 6 months study triggering receptor expressed on myeloid cells 2 directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 2 human data · 4 preclinical · 3 unclassified
Themes no clear themes
Those 9 do not share a common subject.
-
TREM2 appears across unrelated work on tumor macrophages, microglia, liver fibrosis, MASH, ischemic brain injury and Alzheimer’s disease. The approaches range from single-cell and spatial multi-omics to mRNA lipid nanoparticles, cyclic peptides, gene editing and mitochondrial therapies. Reported mechanisms include macrophage dysfunction, amyloid-stress responses, mitochondrial failure and H4K12 lactylation. The cluster has no shared biological question or clear direction beyond recurring interest in TREM2 as a disease-associated target.
Papers
The 9 papers from the last 6 months that study triggering receptor expressed on myeloid cells 2 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (9)
- PMID 41926312
- Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Phage Display-Derived Cyclic Peptides Target TREM2 and Modulate Microglial Responses Under Amyloid Stress. ACS chemical neuroscience · 19 Aug 2026 PMID 42615638
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice. Neurochemical research · 13 Jul 2026 PMID 42443448
- Labile iron starvation in embryonic Kupffer cells aggravates MASH via mitochondrial failure and macrophage dysfunction. Cell death & disease · 17 Jun 2026 PMID 42310295
- H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis. Hepatology (Baltimore, Md.) · 17 Jun 2026 PMID 42307631
- Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants. Acta neuropathologica · 15 Jun 2026 PMID 42298074
- Enhanced neuroprotective effects of remdesivir-loaded solid lipid nanoparticles in ethanol-induced neurodegenerative model: Role of TREM/PPARγ/NLRP3. Alcohol (Fayetteville, N.Y.) · 28 Apr 2026 PMID 42049103
By study type
Human data, design not indexed (2)
- Mechanisms of increased Alzheimer's disease pathology with R47H and R62H TREM2 variants. Acta neuropathologica · 15 Jun 2026 PMID 42298074
- Identification of a novel aβ-overlapping binding site on the TREM2 Ectodomain engaged by the small-molecule agonist VG-3927. Bioorganic & medicinal chemistry letters · 11 Jun 2026 PMID 42276260
Preclinical: animal, cell and lab studies (4)
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Phage Display-Derived Cyclic Peptides Target TREM2 and Modulate Microglial Responses Under Amyloid Stress. ACS chemical neuroscience · 19 Aug 2026 PMID 42615638
- Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice. Neurochemical research · 13 Jul 2026 PMID 42443448
- Enhanced neuroprotective effects of remdesivir-loaded solid lipid nanoparticles in ethanol-induced neurodegenerative model: Role of TREM/PPARγ/NLRP3. Alcohol (Fayetteville, N.Y.) · 28 Apr 2026 PMID 42049103
Unclassified: not yet indexed with MeSH (3)
- Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914
- Labile iron starvation in embryonic Kupffer cells aggravates MASH via mitochondrial failure and macrophage dysfunction. Cell death & disease · 17 Jun 2026 PMID 42310295
- H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis. Hepatology (Baltimore, Md.) · 17 Jun 2026 PMID 42307631
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-16. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.